Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.
Autoimmune (NZB X NZW) F1 female hybrid mice were treated with LS-2616, a recently developed substance with immunomodulating properties. Treatment was initiated at the age of 4 months (i.e. at the early stage of the disease) as well as at 7 months of age (i.e. after the development of established lupus-like disease). Control groups treated with cyclophosphamide and physiological saline were also studied. Beneficial therapeutic effects were obtained regardless of when the treatment was initiated and the dose of LS-2616 administered (1 and 8 mg/mouse/week). The effects of LS-2616 on longevity, splenomegaly and glomerulonephritis were pronounced and sometimes comparable to those of cyclophosphamide (1.8 mg/mouse/week). The results obtained suggest that LS-2616 may be useful in the treatment of autoimmune disease in man.
D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D003176:Complement C3 / Q000032:analysis; D005260:Female; D006912:Hydroxyquinolines / Q000627:therapeutic use*; D007136:Immunoglobulins / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000401:mortality / Q000517:prevention & control*; D008181:Lupus Nephritis / Q000276:immunology / Q000517:prevention & control; D051379:Mice
D003176:Complement C3; D006912:Hydroxyquinolines; D007136:Immunoglobulins; C045282:roquinimex